AN2 Therapeutics, Inc.
Index- P/E- EPS (ttm)-12.50 Insider Own0.70% Shs Outstand19.40M Perf Week-0.95%
Market Cap153.15M Forward P/E- EPS next Y-2.65 Insider Trans172.84% Shs Float5.54M Perf Month-46.11%
Income- PEG- EPS next Q-0.49 Inst Own46.10% Short Float0.72% Perf Quarter-47.37%
Sales- P/S- EPS this Y-92.40% Inst Trans- Short Ratio0.58 Perf Half Y-
Book/sh36.28 P/B0.23 EPS next Y-17.30% ROA- Target Price24.67 Perf Year-
Cash/sh6.42 P/C1.29 EPS next 5Y- ROE- 52W Range6.88 - 23.58 Perf YTD-46.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.76% Beta-
Dividend %- Quick Ratio23.50 Sales past 5Y- Gross Margin- 52W Low20.80% ATR1.66
Employees22 Current Ratio23.50 Sales Q/Q- Oper. Margin- RSI (14)39.35 Volatility15.39% 18.59%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.75 Prev Close8.16
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume68.54K Price8.31
Recom1.50 SMA20-11.52% SMA50-34.93% SMA200-37.55% Volume53,219 Change1.84%
Jul-01-22 10:39AM  
Jun-29-22 07:00AM  
Jun-27-22 09:19AM  
May-10-22 04:10PM  
May-09-22 07:00AM  
Apr-18-22 09:30AM  
Mar-28-22 10:33AM  
Mar-25-22 04:40PM  
Mar-24-22 10:32PM  
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 21Buy7.993022,4133,748,389Jun 23 04:31 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 14Buy7.9761,424489,4023,748,087Jun 15 04:25 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 13Buy7.9020,000158,0003,686,663Jun 15 04:25 PM